Company news
Biophytis SA news in 2025
Biophytis SA's news releases, calls and decks from 2025, newest first.
Biophytis: All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Group and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 31% of the shareholders present or…
November 13, 2025
Biophytis S A Reports First-Half 2025 Results and Provides Strategic Update
October 30, 2025
Biophytis S A dévoile les résultats du premier semestre 2025 et fait le point sur sa stratégie
October 30, 2025
Biophytis S A and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia
October 13, 2025
Biophytis S A to Participate in Four Key Events in Q4 2025
September 30, 2025
Biophytis S A annonce sa participation à quatre événements clés au cours du 4ème trimestre 2025
September 30, 2025
Biophytis S A Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
September 15, 2025
Biophytis S A obtient un financement public au Brésil pour l’essai de Phase 2 dans l’obésité et signe des accords avec des centres cliniques locaux de premier plan
September 15, 2025
Biophytis S A unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
September 11, 2025
Biophytis S A obtient l'autorisation de l'EMA pour le lancement de son étude clinique de phase 2 dans l’obésité
September 3, 2025
Biophytis S A obtains EMA authorization to launch its Phase 2 clinical trial in obesity
September 3, 2025
Decks in 2025
- Investor Presentation (January 2025)
Investor deck · 32 slides · January 2025